---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-021353"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:47:10.882925+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma amends bylaws to streamline director count setting

## Summary
- Board of Directors approved amendment to Section 3.02 of Bylaws on May 23, 2024, effective immediately.
- Previous language required a majority of total directors (including vacancies) to set board size; now any board resolution suffices.
- Authorized board size remains unchanged at minimum 3 and maximum 9 directors.

## SEC filing metadata
- accession: 0001493152-24-021353
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315224021353/0001493152-24-021353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315224021353/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-021353
- JSON: https://secwatch.observer/filing/0001493152-24-021353.json
- Plain text: https://secwatch.observer/filing/0001493152-24-021353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.